CoChat

Glucagon-like peptide-1 increases heart rate by a direct action on the sinus node

Open access
Lubberding, Anniek Frederike, Veedfald, Simon, Achter, Jonathan Samuel, Nissen, Sarah Dalgas, Soattin, Luca, Sorrentino, Andrea, Vega, Estefania Torres, Linz, Benedikt, Eggertsen, Caroline Harriet Eggert, Mulvey, John, Toräng, Signe, Larsen, Sara Agnete, Nissen, Anne, Petersen, Lonnie Grove, Bilir, Secil Erbil, Bentzen, Bo Hjorth, Rosenkilde, Mette Marie, Hartmann, Bolette, Lilleør, Thomas Nikolaj Bang, Qazi, Saddiq, Møller, Christian Holdflod, Tfelt-Hansen, Jacob, Sattler, Stefan Michael, Jespersen, Thomas, Holst, Jens Juul, Lundby, Alicia · 2024 · Cardiovascular Research
Cited by 84

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Abstract

Aims: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used to treat type 2 diabetes and obesity. Albeit cardiovascular outcomes generally improve, treatment with GLP-1 RAs is associated with increased heart rate, the mechanism of which is unclear. Methods and results: We employed a large animal model, the female landrace pig, and used multiple in vivo and ex vivo approaches including pharmacological challenges, electrophysiology, and high-resolution mass spectrometry to explore how GLP-1 elicits an increase in heart rate. In anaesthetized pigs, neither cervical vagotomy, adrenergic blockers (alpha, beta, or combined alpha-beta blockade), ganglionic blockade (hexamethonium), nor inhibition of hyperpolarization-activated cyclic nucleotide–gated (HCN) channels (ivabradine) abolished the marked chronotropic effect of GLP-1. GLP-1 administration to isolated perfused pig hearts also increased heart rate, which was abolished by GLP-1 receptor blockade. Electrophysiological characterization of GLP-1 effects in vivo and in isolated perfused hearts localized electrical modulation to the atria and conduction system. In isolated sinus nodes, GLP-1 administration shortened the action potential cycle length of pacemaker cells and shifted the site of earliest activation. The effect was independent of HCN blockade. Collectively, these data support a direct effect of GLP-1 on GLP-1 receptors within the heart. Consistently, single nucleus RNA sequencing showed GLP-1 receptor expression in porcine pacemaker cells. Quantitative phosphoproteomics analyses of sinus node samples revealed that GLP-1 administration leads to phosphorylation changes of calcium cycling proteins of the sarcoplasmic reticulum, known to regulate heart rate. Conclusion: GLP-1 has direct chronotropic effects on the heart mediated by GLP-1 receptors in pacemaker cells of the sinus node, inducing changes in action potential morphology and the leading pacemaker site through a calcium signalling response characterized by PKA-dependent phosphorylation of Ca2+ cycling proteins involved in pacemaking. Targeting the pacemaker calcium clock may be a strategy to lower heart rate in people treated with GLP-1 RAs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cvr/cvae120

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Research works printed but not linked: 36

  1. Gerstein, 2019, Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial, Lancet, 394, 121, 10.1016/S0140-6736(19)31149-3 · DOI · Paper page
  2. Holman, 2017, Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes, N Engl J Med, 377, 1228, 10.1056/NEJMoa1612917 · DOI · Paper page
  3. Husain, 2019, Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes, N Engl J Med, 381, 841, 10.1056/NEJMoa1901118 · DOI · Paper page
  4. Dave, 2020, Trends in clinical characteristics and prescribing preferences for SGLT2 inhibitors and GLP-1 receptor agonists, 2013-2018, Diabetes Care, 43, 921, 10.2337/dc19-1943 · DOI · Paper page
  5. Marx, 2022, GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes, Circulation, 146, 1882, 10.1161/CIRCULATIONAHA.122.059595 · DOI · Paper page
  6. Perret-Guillaume, 2009, Heart rate as a risk factor for cardiovascular disease, Prog Cardiovasc Dis, 52, 6, 10.1016/j.pcad.2009.05.003 · DOI · Paper page
  7. Buse, 2013, Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study, Lancet, 381, 117, 10.1016/S0140-6736(12)61267-7 · DOI · Paper page
  8. Pratley, 2018, Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial, Lancet Diabetes Endocrinol, 6, 275, 10.1016/S2213-8587(18)30024-X · DOI · Paper page
  9. Bohm, 2010, Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial, Lancet, 376, 886, 10.1016/S0140-6736(10)61259-7 · DOI · Paper page
  10. Baggio, 2017, The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice, Mol Metab, 6, 1339, 10.1016/j.molmet.2017.08.010 · DOI · Paper page
  11. Griffioen, 2011, GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons, Cardiovasc Res, 89, 72, 10.1093/cvr/cvq271 · DOI · Paper page
  12. Ang, 2018, Modulation of cardiac ventricular excitability by GLP-1 (glucagon-like peptide-1), Circ Arrhythm Electrophysiol, 11, e006740, 10.1161/CIRCEP.118.006740 · DOI · Paper page
  13. Jøns, 2021, Mechanism of and strategy to mitigate liraglutide-mediated positive chronotropy, Life Sci, 282, 119815, 10.1016/j.lfs.2021.119815 · DOI
  14. Asmar, 2016, Glucagon-like peptide-1 does not have acute effects on central or renal hemodynamics in patients with type 2 diabetes without nephropathy, Am J Physiol Endocrinol Metab, 310, E744, 10.1152/ajpendo.00518.2015 · DOI · Paper page
  15. Clauss, 2019, Animal models of arrhythmia: classic electrophysiology to genetically modified large animals, Nat Rev Cardiol, 16, 457, 10.1038/s41569-019-0179-0 · DOI · Paper page
  16. van Opbergen, 2022, Exercise causes arrhythmogenic remodeling of intracellular calcium dynamics in plakophilin-2-deficient hearts, Circulation, 145, 1480, 10.1161/CIRCULATIONAHA.121.057757 · DOI · Paper page
  17. Vinogradova, 2006, High basal protein kinase A-dependent phosphorylation drives rhythmic internal Ca2+ store oscillations and spontaneous beating of cardiac pacemaker cells, Circ Res, 98, 505, 10.1161/01.RES.0000204575.94040.d1 · DOI · Paper page
  18. Lundby, 2013, In vivo phosphoproteomics analysis reveals the cardiac targets of beta-adrenergic receptor signaling, Sci Signal, 6, rs11, 10.1126/scisignal.2003506 · DOI · Paper page
  19. Lubberding, 2023, Cardiovascular endocrinology and metabolism, 365, 10.1016/B978-0-323-99991-5.00017-6 · DOI
  20. Daghlas, 2021, Genetic evidence for repurposing of GLP1R (glucagon-like peptide-1 receptor) agonists to prevent heart failure, J Am Heart Assoc, 10, e020331, 10.1161/JAHA.120.020331 · DOI
  21. Kumarathurai, 2016, Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study, Cardiovasc Diabetol, 15, 105, 10.1186/s12933-016-0425-2 · DOI · Paper page
  22. Monami, 2017, Glucagon-like peptide-1 receptor agonists and atrial fibrillation: a systematic review and meta-analysis of randomised controlled trials, J Endocrinol Invest, 40, 1251, 10.1007/s40618-017-0698-7 · DOI
  23. Wu, 2022, Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized controlled trials, Diabetol Metab Syndr, 14, 195, 10.1186/s13098-022-00970-2 · DOI
  24. Axelsen, 2012, Glucagon and a glucagon-GLP-1 dual-agonist increases cardiac performance with different metabolic effects in insulin-resistant hearts, Br J Pharmacol, 165, 2736, 10.1111/j.1476-5381.2011.01714.x · DOI · Paper page
  25. Wettergren, 1998, Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow, Am J Physiol, 275, G984
  26. Plamboeck, 2013, The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty, Am J Physiol Gastrointest Liver Physiol, 304, G1117, 10.1152/ajpgi.00035.2013 · DOI · Paper page
  27. Tougaard, 2020, Heart rate increases in liraglutide treated chronic heart failure patients: association with clinical parameters and adverse events, Scand Cardiovasc J, 54, 294, 10.1080/14017431.2020.1751873 · DOI
  28. Serre, 1998, Exendin-(9-39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: implications for basal intracellular cyclic adenosine 3’,5'-monophosphate levels and beta-cell glucose competence, Endocrinology, 139, 4448, 10.1210/endo.139.11.6295 · DOI · Paper page
  29. MacDonald, 2020, Neurohumoral control of sinoatrial node activity and heart rate: insight from experimental models and findings from humans, Front Physiol, 11, 170, 10.3389/fphys.2020.00170 · DOI
  30. Brennan, 2020, Evidence of superior and inferior sinoatrial nodes in the mammalian heart, JACC Clin Electrophysiol, 6, 1827, 10.1016/j.jacep.2020.09.012 · DOI
  31. Monfredi, 2010, The anatomy and physiology of the sinoatrial node–a contemporary review, Pacing Clin Electrophysiol, 33, 1392, 10.1111/j.1540-8159.2010.02838.x · DOI · Paper page
  32. Dalsgaard, 2018, Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: a narrative review of head-to-head comparisons, Diabetes Obes Metab, 20, 508, 10.1111/dom.13128 · DOI · Paper page
  33. Wallner, 2015, Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium: GLP-1R mediated effects in human myocardium, J Mol Cell Cardiol, 89, 365, 10.1016/j.yjmcc.2015.09.018 · DOI
  34. Linscheid, 2019, Quantitative proteomics and single-nucleus transcriptomics of the sinus node elucidates the foundation of cardiac pacemaking, Nat Commun, 10, 2889, 10.1038/s41467-019-10709-9 · DOI
  35. Maltsev, 2008, Dynamic interactions of an intracellular Ca2+ clock and membrane ion channel clock underlie robust initiation and regulation of cardiac pacemaker function, Cardiovasc Res, 77, 274, 10.1093/cvr/cvm058 · DOI
  36. Wainger, 2001, Molecular mechanism of cAMP modulation of HCN pacemaker channels, Nature, 411, 805, 10.1038/35081088 · DOI · Paper page

Cited by

See all 84

Metadata

Authors
Lubberding, A. F., Veedfald, S., Achter, J. S., Nissen, S. D., Soattin, L., Sorrentino, A., Vega, E. T., Linz, B., Eggertsen, C. H. E., Mulvey, J., Toräng, S., Larsen, S. A., Nissen, A., Petersen, L. G., Bilir, S. E., Bentzen, B. H., Rosenkilde, M. M., Hartmann, B., Lilleør, T. N. B., Qazi, S., Møller, C. H., Tfelt-Hansen, J., Sattler, S. M., Jespersen, T., Holst, J. J., & Lundby, A.
Venue
Cardiovascular Research
Published
2024-06-04
Volume
120
Issue
12
Pages
1427-1441
ISSN
  • 0008-6363 (ISSN-L)
  • 1755-3245
OpenAlex
W4399327314
Cited by
84
References
40
FWCI
22.56
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glucagon-like peptide-1 increases heart rate by a direct action on the sinus node. https://app.cochat.ai/papers/10.1093/cvr/cvae120
The paper
Lubberding, A. F., Veedfald, S., Achter, J. S., Nissen, S. D., Soattin, L., Sorrentino, A., Vega, E. T., Linz, B., Eggertsen, C. H. E., Mulvey, J., Toräng, S., Larsen, S. A., Nissen, A., Petersen, L. G., Bilir, S. E., Bentzen, B. H., Rosenkilde, M. M., Hartmann, B., Lilleør, T. N. B., . . . Lundby, A. (2024). Glucagon-like peptide-1 increases heart rate by a direct action on the sinus node. Cardiovascular Research. https://doi.org/10.1093/cvr/cvae120

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.